A phase 1 multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity, and antitumor activity of MEDI7247 in patients with select relapsed/refractory hematologic malignancies.
2018
TPS2603Background: Survival outcomes in patients with relapsed/refractory multiple myeloma (MM), acute myeloid leukemia (AML), or diffuse large B-cell lymphoma (DLBCL) remains poor, and there is a ...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI